Alimera Sciences (NASDAQ:ALIM) Upgraded at StockNews.com

Alimera Sciences (NASDAQ:ALIM) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

Separately, Maxim Group started coverage on Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 target price on the stock.

Alimera Sciences Price Performance

Alimera Sciences stock opened at $3.59 on Monday. The business’s 50-day simple moving average is $3.71 and its 200 day simple moving average is $3.62. The stock has a market cap of $187.94 million, a price-to-earnings ratio of -1.66 and a beta of 1.18. Alimera Sciences has a 12-month low of $1.56 and a 12-month high of $4.38. The company has a quick ratio of 2.31, a current ratio of 2.39 and a debt-to-equity ratio of 1.40.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The firm had revenue of $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. During the same quarter in the prior year, the business earned ($0.54) EPS. As a group, research analysts anticipate that Alimera Sciences will post 0.03 earnings per share for the current year.

Institutional Investors Weigh In On Alimera Sciences

Hedge funds have recently modified their holdings of the business. Worth Venture Partners LLC acquired a new stake in shares of Alimera Sciences during the third quarter worth about $1,840,000. AIGH Capital Management LLC acquired a new stake in shares of Alimera Sciences during the third quarter worth about $7,355,000. Finally, Stonepine Capital Management LLC acquired a new stake in Alimera Sciences in the 3rd quarter valued at approximately $12,349,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).